Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

Blood (2023) 142 (Supplement 1): 6363.

https://doi.org/10.1182/blood-2023-188523

Published: 2023

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Blood (2022) 140 (Supplement 1): 4420–4422.

https://doi.org/10.1182/blood-2022-165942

Published: 2022

Journal Articles

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Blood (2022) 140 (Supplement 1): 4409–4411.

https://doi.org/10.1182/blood-2022-156390

Published: 2022

Journal Articles

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Blood (2021) 138 (Supplement 1): 1262.

https://doi.org/10.1182/blood-2021-153028

Published: 2021

Journal Articles

Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-136302

Published: 2020

Journal Articles

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-136907

Published: 2020

Journal Articles

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

Giorgina Specchia, MD, Patrizia Pregno, Massimo Breccia, MD, Chiara Monagheddu, Fausto Castagnetti, MDPhD, Massimiliano Bonifacio, MD, Mario Tiribelli, MD, Fabio Stagno, MD PhD, Giovanni Caocci, MD, Bruno Martino, MD, Luigiana Luciano, MD, Michele Pizzuti, MD, Antonella Gozzini, MD, Anna Rita Scortechini, MD, Francesco Albano, Micaela Bergamaschi, MD, Isabella Capodanno, MD, Andrea Patriarca, MD, Carmen Fava, Giovanna Rege Cambrin, MDPhD, Federica Sorà, MD, Sara Galimberti, MD PhD, Monica Bocchia, Gianni Binotto, MD, Giovanni Reddiconto, Attilio Guarini, MD, Alessandro Maggi, Grazia Sanpaolo, MD, Maria Stella De Candia, Valentina Giai, MD PhD, Elisabetta Abruzzese, MD, Maria Cristina Miggiano, MD, Franca Falzetti, MD, Gaetano La Barba, Giuseppe Pietrantuono, Anna Guella, MD, Luciano Levato, MD, Olga Mulas, Fabio Saccona, Gianantonio Rosti, MD, Pellegrino Musto, MD, Francesco Di Raimondo, MD, Fabrizio Pane, MD, Robin Foà, MD, Michele Baccarani, MD, Giovannino Ciccone, Giuseppe Saglio, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-139307

Published: 2020

Journal Articles

Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

Blood (2016) 128 (22): 4494.

https://doi.org/10.1182/blood.V128.22.4494.4494

Published: 2016

Journal Articles

Characterization and Prognostic Relevance of Circulating Microvesicles in Chronic Lymphocytic Leukemia

Luciana De Luca, Giovanni D'Arena, MD, Vittorio Simeon, PhD, Stefania Trino, PhD, Ilaria Laurenzana, PhD, Antonella Caivano, Francesco La Rocca, Oreste Villani, MD, Giovanna Mansueto, MD, Silvia Deaglio, MD PhD, Idanna Innocenti, MD, Luca Laurenti, Stefano Molica, MD, Giuseppe Pietrantuono, MD, Angelo De Stradis, Luigi Del Vecchio, MD, Pellegrino Musto, MD

Blood (2016) 128 (22): 4375.

https://doi.org/10.1182/blood.V128.22.4375.4375

Published: 2016

Journal Articles

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Blood (2016) 127 (9): 1102–1108.

https://doi.org/10.1182/blood-2015-08-662627

Published: 2016

Includes: Supplemental data

Journal Articles

EphA3 As a Molecular Target In Multiple Myeloma: Opportunity For a Novel Therapeutic Approach With a Specific Monoclonal Antibody

Blood (2013) 122 (21): 3211.

https://doi.org/10.1182/blood.V122.21.3211.3211

Published: 2013

Journal Articles

A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients

Blood (2013) 122 (21): 536.

https://doi.org/10.1182/blood.V122.21.536.536

Published: 2013

Journal Articles

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

Blood (2013) 122 (8): 1376–1383.

https://doi.org/10.1182/blood-2013-02-483073

Published: 2013

Includes: Supplemental data

Journal Articles

No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura

Giovanni D'Arena, Roberto Guariglia, Giovanna Mansueto, Maria Carmen Martorelli, Giuseppe Pietrantuono, Oreste Villani, Rosa Lerose, Pellegrino Musto

Blood (2013) 121 (7): 1240–1242.

https://doi.org/10.1182/blood-2012-11-465575

Published: 2013

Journal Articles

Identification of EpHA3 As a New Potential Molecular Target in Multiple Myeloma.

Antonella Caivano, Francesco La Rocca, Alessandra Favole, PhD, Sonia Carturan, PhD, Enrico Bracco, PhD, Oreste Villani, Giuseppe Pietrantuono, Ilaria Laurenzana, Luciana De Luca, MD, Annalisa Morano, Vittorio Simeon, Stefania Trino, Simona Berardi, Antonio Basile, Angelo Vacca, Pellegrino Musto, Daniela Cilloni, MD

Blood (2012) 120 (21): 2926.

https://doi.org/10.1182/blood.V120.21.2926.2926

Published: 2012

Journal Articles

Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.

Blood (2012) 120 (21): 2971.

https://doi.org/10.1182/blood.V120.21.2971.2971

Published: 2012

Journal Articles

Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia

Blood (2012) 120 (21): 729.

https://doi.org/10.1182/blood.V120.21.729.729

Published: 2012

Journal Articles

Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia

Blood (2011) 118 (21): 2925.

https://doi.org/10.1182/blood.V118.21.2925.2925

Published: 2011

Journal Articles

Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?

Blood (2011) 118 (21): 2770.

https://doi.org/10.1182/blood.V118.21.2770.2770

Published: 2011

Journal Articles

Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors

Blood (2010) 116 (21): 620.

https://doi.org/10.1182/blood.V116.21.620.620

Published: 2010

NARROW

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study

Characterization and Prognostic Relevance of Circulating Microvesicles in Chronic Lymphocytic Leukemia

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

EphA3 As a Molecular Target In Multiple Myeloma: Opportunity For a Novel Therapeutic Approach With a Specific Monoclonal Antibody

A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura

Identification of EpHA3 As a New Potential Molecular Target in Multiple Myeloma.

Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients.

Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia

Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia

Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?

Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only